Drug · Monoclonal Antibody
Talquetamab
CI-DRUG-00000762Explore in graph →CHEMBL4594503 Approved
Regulatory
Approvals (4)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as TALVEY (DIN 02547392) under ATC L01FX29 TALQUETAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 4, 2025 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as TALVEY (DIN 02547406) under ATC L01FX29 TALQUETAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 4, 2025 | health-canada-dpd |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 10 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 3 | 31 | 17 | 6 | 35 | 4 | CA, EU, US | Aug 9, 2023 | Dec 16, 2017 |
| Multiple Myeloma | Approved | Phase 3 | 26 | 16 | 5 | 29 | 2 | EU, US | Aug 9, 2023 | Dec 13, 2018 |
| Non-Hodgkin Lymphoma | Approved | Phase 3 | 26 | 16 | 5 | 29 | 2 | EU, US | Aug 9, 2023 | Dec 13, 2018 |
| Leukemia | Phase3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (38)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MonumenTAL-2) | active not recruiting | Phase 1 | 166 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT03399799 | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma |